http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 11 Jan 2026 23:34:19 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) announced the completion of enrollment for the first participants in a Phase 2 clinical trial in Australia evaluating its respiratory combination vaccine candidates SCB-1022 and SCB-1033.</p> <p>The trial will test SCB-1022, which combines respiratory syncytial virus and human metapneumovirus components, and SCB-1033, which adds parainfluenza virus type 3 to the combination. Both vaccines use protein-based antigens with Clover's Trimer-Tag technology platform.</p> <p>The Phase 2 study is a randomized, observer-blinded, multi-center trial enrolling up to 420 adults aged 60-85 years in Australia. Participants will receive either SCB-1022, SCB-1033, or placebo. The study aims to assess safety, reactogenicity and http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html Sun, 11 Jan 2026 23:34:19 -0500 02197 2197 O.52926870 http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) announced the completion of enrollment for the first participants in a Phase 2 clinical trial in Australia evaluating its respiratory combination vaccine candidates SCB-1022 and SCB-1033.</p> <p>The trial will test SCB-1022, which combines respiratory syncytial virus and human metapneumovirus components, and SCB-1033, which adds parainfluenza virus type 3 to the combination. Both vaccines use protein-based antigens with Clover's Trimer-Tag technology platform.</p> <p>The Phase 2 study is a randomized, observer-blinded, multi-center trial enrolling up to 420 adults aged 60-85 years in Australia. Participants will receive either SCB-1022, SCB-1033, or placebo. The study aims to assess safety, reactogenicity and http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html Sun, 11 Jan 2026 23:34:19 -0500 02197 2197 O.52926870 http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) announced the completion of enrollment for the first participants in a Phase 2 clinical trial in Australia evaluating its respiratory combination vaccine candidates SCB-1022 and SCB-1033.</p> <p>The trial will test SCB-1022, which combines respiratory syncytial virus and human metapneumovirus components, and SCB-1033, which adds parainfluenza virus type 3 to the combination. Both vaccines use protein-based antigens with Clover's Trimer-Tag technology platform.</p> <p>The Phase 2 study is a randomized, observer-blinded, multi-center trial enrolling up to 420 adults aged 60-85 years in Australia. Participants will receive either SCB-1022, SCB-1033, or placebo. The study aims to assess safety, reactogenicity and http://www.streetinsider.com/FDA/Clover+begins+phase+2+trial+for+respiratory+combination+vaccines/25832799.html Sun, 11 Jan 2026 23:34:19 -0500 02197 2197 O.52926870 http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/Press+Releases/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html <div class="xn-content"> <p class="prntac"><i>-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates --</i></p><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Jan. 12, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.cloverbiopharma.com/" target="_blank" rel="nofollow"><span value="HongKong:2197" idsrc="xmltag.org" >Clover Biopharmaceuticals</span>, Ltd. </a>(Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase 2 clinical trial in <location value="LC/au" idsrc="xmltag.org" >Australia</location> evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) http://www.streetinsider.com/PRNewswire/Clover+Initiates+Phase+2+Clinical+Trial+for+RSV+%2B+hMPV+%C2%B1+PIV3+Respiratory+Combination+Vaccine+Candidates/25832798.html Sun, 11 Jan 2026 23:33:00 -0500 02197 2197 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as president of global research and development and alliances, the Shanghai-based biotechnology company announced.</p> <p>Jackson will collaborate with Chief Executive Officer Joshua Liang to advance the company's RSV+hMPV±PIV3 combination vaccine candidates and establish partnerships with global collaborators, according to the company statement.</p> <p>Jackson brings 27 years of experience in vaccine and infectious disease research and development. He previously held leadership roles at GSK, Pfizer, and Sanofi, where he served as head of global research for Sanofi Pasteur. Most recently, he was executive director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+president+of+global+R%26D/25472555.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as President of Global R&D and Alliances, according to a company statement. Jackson will work with CEO Joshua Liang to advance development of the company's RSV+hMPV±PIV3 combination vaccine candidates and lead potential partnerships with global collaborators.</p> <p>Jackson returns to Clover after previously holding leadership positions at GSK, Pfizer and Sanofi, where he served as Head of Global Research for Sanofi Pasteur. Most recently, he was Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity.</p> <p>"His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as President of Global R&D and Alliances, according to a company statement. Jackson will work with CEO Joshua Liang to advance development of the company's RSV+hMPV±PIV3 combination vaccine candidates and lead potential partnerships with global collaborators.</p> <p>Jackson returns to Clover after previously holding leadership positions at GSK, Pfizer and Sanofi, where he served as Head of Global Research for Sanofi Pasteur. Most recently, he was Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity.</p> <p>"His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as President of Global R&D and Alliances, according to a company statement. Jackson will work with CEO Joshua Liang to advance development of the company's RSV+hMPV±PIV3 combination vaccine candidates and lead potential partnerships with global collaborators.</p> <p>Jackson returns to Clover after previously holding leadership positions at GSK, Pfizer and Sanofi, where he served as Head of Global Research for Sanofi Pasteur. Most recently, he was Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity.</p> <p>"His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870 http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html <p>Clover Biopharmaceuticals Ltd. (HKEX: 02197) appointed Nicholas Jackson as President of Global R&D and Alliances, according to a company statement. Jackson will work with CEO Joshua Liang to advance development of the company's RSV+hMPV±PIV3 combination vaccine candidates and lead potential partnerships with global collaborators.</p> <p>Jackson returns to Clover after previously holding leadership positions at GSK, Pfizer and Sanofi, where he served as Head of Global Research for Sanofi Pasteur. Most recently, he was Executive Director and CEO of the Novo Nordisk Foundation Initiative for Vaccines and Immunity.</p> <p>"His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as http://www.streetinsider.com/Management+Changes/Clover+Biopharmaceuticals+names+Nicholas+Jackson+as+president+of+global+R%26D/25472556.html Sun, 19 Oct 2025 19:00:12 -0500 02197 2197 A.02264286 A.02973684 A.08612854 A.27755148 A.41780024 O.00285735 O.00338863 O.00573607 O.00573640 O.52926870